

Supplementary Table S1. Clinical characteristics of all SSc patients enrolled in the study.

	Age at collection of stool sample	Gender	Ethnicity	Disease duration from non-Raynaud's phenomenon onset at time of collection of stool sample (years)	SSc subtype	Serology	IS at collection of stool sample	Organ involvement
SSc On-IS (n=12)								
Subject 1	40	F	C	3.3	LcSSc	ANA	AZA	Vas, ILD, GI
Subject 2	59	F	C	8.0	LcSSc	ANA, RNA	MMF	Ar, Vas, ILD, GI
Subject 3	63	F	C	23.0	LcSSc	ANA	MMF	Ar, Vas, Myo, ILD, GI
Subject 4	59	F	C	2.6	DcSSc	ANA, Scl70, RNA	CYC	Ar, Vas, ILD, GI
Subject 5	62	F	C	2.1	LcSSc	ANA	MMF	Vas, ILD, GI
Subject 6	50	F	C	5.2	LcSSc	ANA, Scl70	CYC	Ar, Vas, ILD, GI
Subject 7	59	F	C	10.5	LcSSc	Scl70	MTX	Ar, Vas, ILD, GI
Subject 8	42	F	C	1.5	LcSSc	ANA, ACA	MTX	Ar, Vas, GI
Subject 9	45	F	C	1.2	LcSSc	ANA, Scl70	MTX	Ar, Vas, Myo, GI
Subject 10	33	F	M	5.3	LcSSc	ANA, Scl70	CYC	Ar, Vas, ILD, PH, GI
Subject 11	36	F	I	1.5	DcSSc	ANA, Scl70	CYC	Ar, Vas, Myo, Car, ILD, GI
Subject 12	50	F	C	0.7	LcSSc	ANA	MMF	Ar, Vas, Myo, GI
SSc No-IS (n=11)								
Subject 13	48	F	C	2.3	DcSSc	ANA, Scl70	-	Ar, Vas, ILD, GI
Subject 14	60	F	C	0.7	DcSSc	ANA	-	Ar, Myo, GI
Subject 15	51	F	C	7.6	LcSSc	ANA, ACA	-	Vas, GI
Subject 16	58	F	C	0.2	DcSSc	ANA, Scl70	-	Ar, ILD, GI
Subject 17	55	F	C	1.1	LcSSc	ANA, ACA	-	Ar, Vas, GI
Subject 18	51	F	C	6.2	LcSSc	ANA	-	Ar, Vas, Myo, GI
Subject 19	54	F	C	8.8	LcSSc	ANA, ACA	-	Ar, Vas, ILD, GI
Subject 20	59	F	C	11.7	LcSSc	ANA, ACA	-	Vas, GI
Subject 21	56	F	C	7.2	LcSSc	ANA	-	Ar, Vas, GI
Subject 22	67	F	C	15.9	LcSSc	ANA	-	Ar, Vas, ILD, GI
Subject 23	49	F	C	0.2	LcSSc	ANA	-	Ar, Vas, Myo, GI

Ar: arthritis; ACA: anti-centromere antibody; ANA: anti-nuclear antibody; AZA: azathioprine; C: Chinese; Car: cardiac involvement based on arrhythmia requiring treatment and raised troponin-T; CYC: cyclophosphamide; DcSSc: diffuse cutaneous SSc patient; GI: gastrointestinal tract; I: Indian; ILD: interstitial lung disease based on high-resolution computed tomography scan; LcSSc: limited cutaneous SSc patient; M: Malay; MMF: mycophenolate mofetil; MTX: methotrexate; Myo: myositis; PH: pulmonary hypertension based on right heart catheterisation; RNA: anti-RNA polymerase III antibody; Scl70: anti-Scl 70 antibody; SSc On-IS: SSc patients on immunosuppression; SSc No-IS: SSc patients not on immunosuppression; Vas: vasculopathy.